Sort
23,748 grants matching “melanoma”
Selective Cancer Treatment Based on High Frequency Ultrasonic Beam
$240,400Eun Sok Kim · University Of Southern California · R21 · FY2016 · EB
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies
$240,368Lee Roy Morgan · Dekk-Tec, Inc. · R44 · FY2018 · CA
SPORE: Targeted Therapies for Glioma
$240,300Tracy T Batchelor · Brigham And Women'S Hospital · P50 · FY2022 · CA
CHEMOKINE RECEPTOR STUDIES
$240,238Vanderbilt University · R01 · FY2000 · CA
INNATE MECHANISMS REGULATING CD8+T CELL IMMUNITY
$240,228Cleveland Clinic Foundation · R01 · FY2003 · AI
Dendritic cell based therapies for murine tumors
$240,192University Of Pittsburgh At Pittsburgh · R01 · FY2001 · CA
IMMUNIZATION AGAINST MELANOMA DIFFERENTIATION ANTIGENS
$240,172Sloan-Kettering Institute For Cancer Res · R01 · FY2001 · CA
SSAT AS A DETERMINANT OF DRUG ACTION
$240,132Roswell Park Cancer Institute Corp · R01 · FY2001 · CA
TISSUE ENGINEERING USING PEPTIDE AMPHIPHILE BIOMIMETICS
$239,909Florida Atlantic University · R01 · FY2000 · HL
TISSUE ENGINEERING USING PEPTIDE AMPHIPHILE BIOMIMETICS
$239,909Florida Atlantic University · R01 · FY2001 · HL
TISSUE ENGINEERING USING PEPTIDE AMPHIPHILE BIOMIMETICS
$239,909Florida Atlantic University · R01 · FY2002 · EB
Overcoming Resistance to RAF Inhibition in BRAF-Mutant Colorectal Cancer
$239,907Levi Alexander Garraway · Dana-Farber Cancer Inst · P50 · FY2016 · CA
Amide Acidity Analysis of Intrinsic and Ligand-induced Flexibility and Allostery
$239,766Griselda Hernandez · Wadsworth Center · R01 · FY2009 · GM
SHP1 Targeted Inhibition by Stibogluconate for Melanoma
$239,656Ernest C. Borden · Cleveland Clinic Lerner Com-Cwru · R01 · FY2007 · CA
Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma
$239,650Gary K Schwartz · Sloan-Kettering Inst Can Research · R01 · FY2009 · FD
The role of marginal zone macrophages and immuno-metabolism in tumor-driven MDSC development
$239,637Tracy L McGaha · University Health Network · R01 · FY2020 · CA
Analytical Chemistry and Pharmacology Core Facility
$239,629William C Zamboni · Univ Of North Carolina Chapel Hill · P30 · FY2012 · CA
Dendritic cell based therapies for murine tumors
$239,574University Of Pittsburgh At Pittsburgh · R01 · FY2002 · CA
Tumor Growth and Microenvironment Influence T Cell Tolerance to Tumor Antigens
$239,544Arthur Hurwitz · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Melanoma vaccines
$239,528University Of Washington · R01 · FY2005 · CA
Overcoming Resistance to RAF Inhibition in BRAF-Mutant Colorectal Cancer
$239,495Levi Alexander Garraway · Dana-Farber Cancer Inst · P50 · FY2014 · CA
Mechanism of Chaperone-Mediated Tumor Rejection
$239,473Christopher V Nicchitta · Duke University · R01 · FY2008 · CA
Mechanism of Chaperone-Mediated Tumor Rejection
$239,473Christopher V Nicchitta · Duke University · R01 · FY2007 · CA
The PKCepsilon-regulated oncogenic and tumor suppressor roles of ATF2 in melanoma
$239,410Eric Kirk Lau · H. Lee Moffitt Cancer Ctr & Res Inst · R00 · FY2017 · CA
Role of HOS in Cell Transformation and Apoptosis
$239,401Serge Y Fuchs · University Of Pennsylvania · R01 · FY2013 · CA